|1.||Asahara, Takayuki: 20 articles (01/2015 - 08/2002)|
|2.||Porta, Miquel: 15 articles (11/2014 - 01/2002)|
|3.||Huang, Po-Hsun: 13 articles (01/2014 - 06/2007)|
|4.||Dimmeler, Stefanie: 13 articles (01/2011 - 08/2003)|
|5.||Ii, Masaaki: 11 articles (04/2015 - 11/2006)|
|6.||Chen, Jaw-Wen: 11 articles (07/2013 - 06/2007)|
|7.||Fadini, Gian Paolo: 10 articles (01/2015 - 05/2005)|
|8.||Agostini, Carlo: 10 articles (01/2015 - 02/2005)|
|9.||Lerman, Lilach O: 10 articles (01/2015 - 05/2010)|
|10.||Avogaro, Angelo: 10 articles (12/2014 - 02/2005)|
09/01/2011 - "Endothelial progenitor cells (EPC) have been proven to have the efficacy of therapeutic neovascularization in ischemia. "
02/06/2001 - "Echocardiography, performed just before and 28 days after ischemia, disclosed ventricular dimensions that were significantly smaller and fractional shortening that was significantly greater in the EPC group than in the control group by day 28. "
01/01/2012 - "Treatment with EPC has been shown to improve functional outcomes following cardiac and peripheral vascular ischemia. "
11/01/2010 - "Protection against oxidative stress by CuZnSOD may be essential for EPC function and reparative neovascularization after ischemia."
01/01/2012 - "Soon thereafter human HPC began to be used in clinical trials as putative sources of EPC for therapeutic vascular regeneration, especially in myocardial and critical limb ischemias. "
10/01/2010 - "Echocardiography demonstrated that cardiac function in the IGF-1-EPC group was significantly improved compared with the lacZ-EPC control group 12 weeks after myocardial infarction. "
05/01/2011 - "To investigate the therapeutic efficacy of intravenous implanted bone marrow-derived endothelial progenitor cells (BM-EPC) preconditioned with 17β-estradiol in ovariectomized mice model of acute myocardial infarction (AMI). "
05/01/2009 - "We anticipate that with continued development, EPC therapy will become a safe and effective treatment option for patients with acute myocardial infarction or chronic ischemic disease."
07/01/2012 - "EPO improved the efficiency of EPC therapy in mice with myocardial infarction. "
01/01/2012 - "Akt and HO-1 enhance late outgrowth EPC neovascularization, resulting in improved cardiac performance and reduced negative remodeling after myocardial infarction in nude mice. "
01/10/2013 - "In vivo data in E2 group displayed a greater number of homing EPC, decreased fibrosis of LV, and significant improvement in cardiac function. "
05/01/2011 - "LV function and dimensions, capillary density and LV fibrosis were significantly improved in 17β-estradiol + BM-EPC group than in control group [(LVDs: (3.09 ± 0.05) mm vs. (3.27 ± 0.10)mm, P < 0.05; LVDd: (4.18 ± 0.07) mm vs. (4.31 ± 0.05) mm, P < 0.05; FS: (33.0 ± 3.8)% vs. (26.0 ± 3.2)%, P < 0.05; capillary density: (1428 ± 214)/mm² vs. (1070 ± 168)/mm², P < 0.05; ratio of fibrosis: (38.8 ± 4.9)% vs. (49.0 ± 4.6)%, P < 0.05]. "
01/15/2016 - "Echocardiography and histologic analyses demonstrated that both EPC and MSC improved cardiac function and enhanced vascularization, although fibrosis was reduced only in the EPC transplanted hearts. "
11/11/2011 - "Increased EPC survival and angiogenesis in the myocardium of IL-10-treated mice corroborated with improved left ventricular function, reduced infarct size, and fibrosis in the myocardium. "
06/01/2010 - "Administration of EPC into the stenotic kidney restored angiogenic activity, improved MV density, renal hemodynamics and function, decreased fibrosis and oxidative stress, and attenuated endogenous injury signals. "
05/01/2010 - "A growing number of studies report that EPC participate in tumor progression and influence the efficacy of anticancer chemotherapeutics, and thus are attractive targets for cancer treatments. "
09/15/2003 - "EPC may be a better model of human tumor endothelial cells than HUVEC and HMVEC and, thus, may provide an improved cell-based model for second generation antineoplastic antiangiogenic drug discovery."
10/15/1975 - "It is concluded that the "eclipsed" immunologically inactive state of the EPC in mice bearing advanced tumor is not irreversible and that activation of these cells can occur in vivo under certain conditions helped by the presence of tumor-specific antigenic stimulus."
06/15/2014 - "The aim of our study is to inhibit cancer progression by engeneering ECFCs, a subset of EPC, with a lentivirus encoding the anti-tumor uPAR-degrading enzyme MMP12. "
10/01/2013 - "We present a systematic overview of breast EPC and of the most important studies published on this topic in order to make diagnosis and treatment more straightforward for cancer clinicians. "
01/01/2013 - "In conclusion, we demonstrate for the first time that the administration of EPC-secreted factors could become a safe and effective cell-free option to be considered in future therapeutic strategies for stroke. "
03/01/2013 - "Our data demonstrate that ACE2 improves EPC function, via regulating eNOS and Nox pathways, and enhances the efficacy of EPC-based therapy for ischemic stroke."
01/01/2008 - "Moreover, the EPC (E(3)) level was strongly correlated with improved National Institutes of Health Stroke Scale >or=4 on day 21 after IS (P=0.0004). "
02/15/2013 - "We suggest that ET-1 may play a role in pathophysiology of stroke and subsequent EPC mobilisation; however, further studies aimed at the precise elucidation of this issue are required."
02/01/2013 - "Currently, clinical trials for evaluating EPC transfusion in treating ischemic stroke are underway. "
|2.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|7.||Granulocyte Colony-Stimulating Factor (G-CSF)
|1.||Transplantation (Transplant Recipients)
|3.||Drug Therapy (Chemotherapy)
|4.||Tissue Therapy (Cell Therapy)